MariMed (MRMD) vs. Its Peers Head to Head Comparison

MariMed (OTC:MRMD) is one of 55 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare MariMed to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.

Valuation and Earnings

This table compares MariMed and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MariMed	$148.60 million	-$16.03 million	-2.57
MariMed Competitors	$310.35 million	-$49.81 million	-5.55

MariMed’s rivals have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for MariMed and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	0	0	1	4.00
MariMed Competitors	289	566	1084	86	2.48

As a group, “Medicinals & botanicals” companies have a potential upside of 79.97%. Given MariMed’s rivals higher probable upside, analysts clearly believe MariMed has less favorable growth aspects than its rivals.

Risk and Volatility

MariMed has a beta of 3.15, meaning that its share price is 215% more volatile than the S&P 500. Comparatively, MariMed’s rivals have a beta of 1.30, meaning that their average share price is 30% more volatile than the S&P 500.

Institutional and Insider Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 15.8% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 19.0% of MariMed shares are owned by insiders. Comparatively, 21.5% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares MariMed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.95%	1.58%	0.53%
MariMed Competitors	-38.94%	-24.68%	-6.33%

Summary

MariMed beats its rivals on 8 of the 13 factors compared.

MariMed Company Profile

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.